Immunovant CTO sells shares to cover RSU taxes

Immunovant, Inc. reports that Chief Technology Officer Jay S. Stout sold 2,857 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share, with sale prices ranging from $38.18 to $39.05.

Rhea-AI Filing Summary

Immunovant, Inc. reports that Chief Technology Officer Jay S. Stout sold 2,857 shares of common stock on July 23, 2026 at a weighted average price of $38.69 per share, with sale prices ranging from $38.18 to $39.05. The shares were sold to cover tax withholding obligations from the July 17, 2026 vesting of 6,250 restricted stock units from a 100,000-unit grant. After this mandated sell-to-cover transaction, he directly holds 205,341 shares of Immunovant common stock.

Insider Trade Summary

Net Seller: 2,857 shares

Net Sell 1 txn

Insider Stout Jay S

Role Chief Technology Officer

Sold 2,857 shs ($111K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,857	$38.69	$111K

Holdings After Transaction: Common Stock — 205,341 shares (Direct)

Footnotes (2)

1. F1. On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 2,857 shares Weighted average sale price: $38.69 per share Post-transaction holdings: 205,341 shares +3 more

6 metrics

Shares sold 2,857 shares Common stock sold on July 23, 2026 to cover tax withholding

Weighted average sale price $38.69 per share Weighted average for multiple sale transactions between $38.18 and $39.05

Post-transaction holdings 205,341 shares Directly held Immunovant common shares following the reported sale

RSU grant size 100,000 RSUs Restricted stock units granted on April 17, 2023

RSUs vested 6,250 RSUs Portion of the RSU grant that vested on July 17, 2026

Sale price range $38.18–$39.05 per share Range of individual trade prices within the reported sale

Key Terms

restricted stock units, sell to cover, weighted average price, tax withholding obligations

4 terms

restricted stock units financial

"the holder was granted 100,000 restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction involving Immunovant (IMVT) was reported?

Chief Technology Officer Jay S. Stout sold 2,857 shares of Immunovant common stock on July 23, 2026 at a weighted average price of $38.69 per share. The transaction was linked to the vesting of previously granted restricted stock units and was used to satisfy tax obligations.

Why did Immunovant (IMVT) executive Jay S. Stout sell 2,857 shares?

The 2,857 shares were sold to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The company elected to fund these obligations through a mandatory "sell to cover" transaction, which the disclosure states was not a discretionary trade by Stout.

What RSU grant is associated with Jay S. Stout’s Immunovant (IMVT) share sale?

Stout was granted 100,000 restricted stock units (RSUs) on April 17, 2023. Of this grant, 6,250 RSUs vested on July 17, 2026, and the reported share sale relates to covering taxes triggered by the vesting and settlement of those RSUs.

How many Immunovant (IMVT) shares does Jay S. Stout hold after the transaction?

Following the tax-related sale, Jay S. Stout directly holds 205,341 shares of Immunovant common stock. This figure reflects his position after selling 2,857 shares to satisfy tax withholding tied to the vesting of a portion of his restricted stock unit award.

At what prices were the Immunovant (IMVT) shares sold by Jay S. Stout?

The shares were sold at a weighted average price of $38.69 per share, with individual trades executed between $38.18 and $39.05 per share. The disclosure notes that detailed price breakdowns by trade are available upon request from the company or regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 05:57 PM Accepted by SEC EDGAR 07/24/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stout Jay S

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S		2,857(1)	D	$38.69(2)	205,341	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Jay Stout	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)